Loading patent…
AssigneeChildren's Hospital of Eastern Ontario Research Institute Inc.
InventorDavid F. STOJDL
Estimating the term…
The present disclosure concerns an oncolytic virus for the treatment of cancer, such as in brain cancer, for example glioblastoma. The oncolytic virus may exhibit reduced levels of neurotoxicity. The oncolytic virus may be an isolated viral particle capable of producing a cDNA polynucleotide that includes a sequence according to SEQ ID NO: 1 when the virus is in a host cell. The oncolytic virus may be an isolated viral particle that includes an RNA polynuclotide that includes a sequence according to SEQ ID NO: 2. The oncolytic virus may be an isolated viral particle having a genome that includes open reading frames that encode: proteins having sequences comprising SEQ ID NOs: 3, 4, 5, 6 and 7; or variants thereof.
A pharmaceutical composition comprising an isolated recombinant viral particle having a genome comprising open reading frames that encode:
A pharmaceutical composition comprising an isolated viral particle that produces a cDNA polynucleotide when the viral particle is in a host cell, the cDNA polynucleotide comprising:
A pharmaceutical composition comprising an isolated viral particle that produces a cDNA polynucleotide when the viral particle is in a host cell, wherein the cDNA polynucleotide comprises:
A pharmaceutical composition comprising an isolated viral particle comprising an RNA polynucleotide comprising a sequence that is at least 95% identical to SEQ ID NO:2, wherein the pharmaceutical composition comprises a sufficient number of isolated viral particles to provide at least 1e5 plaque forming units (pfu) of the viral particles and is formulated for direct delivery to the central nervous system, outside the blood/brain barrier and/or inside the blood/brain barrier by intrathecal, intracranial or intravenous injection into a human subject.
Dependencies are inferred from the claim text.